Literature DB >> 25217862

Heparan sulfate differences in rheumatoid arthritis versus healthy sera.

Jenny K Sabol1, Wei Wei2, Marcos López-Hoyos3, Youjin Seo2, Armann Andaya1, Julie A Leary1,2.   

Abstract

Heparan sulfate (HS) is a complex and highly variable polysaccharide, expressed ubiquitously on the cell surface as HS proteoglycans (HSPGs), and found in the extracellular matrix as free HS fragments. Its heterogeneity due to various acetylation and sulfation patterns endows a multitude of functions. In animal tissues, HS interacts with a wide range of proteins to mediate numerous biological activities; given its multiple roles in inflammation processes, characterization of HS in human serum has significant potential for elucidating disease mechanisms. Historically, investigation of HS was limited by its low concentration in human serum, together with the complexity of the serum matrix. In this study, we used a modified mass spectrometry method to examine HS disaccharide profiles in the serum of 50 women with rheumatoid arthritis (RA), and compared our results to 51 sera from healthy women. Using various purification methods and online LC-MS/MS, we discovered statistically significant differences in the sulfation and acetylation patterns between populations. Since early diagnosis of RA is considered important in decelerating the disease's progression, identification of specific biomolecule characterizations may provide crucial information towards developing new therapies for suppressing the disease in its early stages. This is the first report of potential glycosaminoglycan biomarkers for RA found in human sera, while acknowledging the obvious fact that a larger population set, and more stringent collection parameters, will need to be investigated in the future.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  2-O-sulfotransferase; 6-O-sulfotransferase; Glycosaminoglycan; Heparan sulfate; Rheumatoid arthritis

Mesh:

Substances:

Year:  2014        PMID: 25217862      PMCID: PMC4407649          DOI: 10.1016/j.matbio.2014.08.016

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  43 in total

Review 1.  Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes.

Authors:  Kay Grobe; Johan Ledin; Maria Ringvall; Katarina Holmborn; Erik Forsberg; Jeffrey D Esko; Lena Kjellén
Journal:  Biochim Biophys Acta       Date:  2002-12-19

2.  Compositional analysis of glycosaminoglycans by electrospray mass spectrometry.

Authors:  J Zaia; C E Costello
Journal:  Anal Chem       Date:  2001-01-15       Impact factor: 6.986

3.  Organ-specific sulfation patterns of heparan sulfate generated by extracellular sulfatases Sulf1 and Sulf2 in mice.

Authors:  Satoshi Nagamine; Michiko Tamba; Hisako Ishimine; Kota Araki; Kensuke Shiomi; Takuya Okada; Tatsuyuki Ohto; Satoshi Kunita; Satoru Takahashi; Ronnie G P Wismans; Toin H van Kuppevelt; Masayuki Masu; Kazuko Keino-Masu
Journal:  J Biol Chem       Date:  2012-02-01       Impact factor: 5.157

4.  Analysis of the biogenesis of heparan sulfate acetyl-CoA:alpha-glucosaminide N-acetyltransferase provides insights into the mechanism underlying its complete deficiency in mucopolysaccharidosis IIIC.

Authors:  Stéphanie Durand; Matthew Feldhammer; Eric Bonneil; Pierre Thibault; Alexey V Pshezhetsky
Journal:  J Biol Chem       Date:  2010-07-22       Impact factor: 5.157

5.  Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking α-l-iduronidase.

Authors:  Rebecca J Holley; Audrey Deligny; Wei Wei; H Angharad Watson; Milady R Niñonuevo; Anders Dagälv; Julie A Leary; Brian W Bigger; Lena Kjellén; Catherine L R Merry
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

Review 6.  Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Ilana Dowek; Ralph D Sanderson; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

Review 7.  Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.

Authors:  Neta Ilan; Michael Elkin; Israel Vlodavsky
Journal:  Int J Biochem Cell Biol       Date:  2006-07-06       Impact factor: 5.085

8.  Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate.

Authors:  Martha L Escobar Galvis; Juan Jia; Xiao Zhang; Nadja Jastrebova; Dorothe Spillmann; Eva Gottfridsson; Toin H van Kuppevelt; Eyal Zcharia; Israel Vlodavsky; Ulf Lindahl; Jin-Ping Li
Journal:  Nat Chem Biol       Date:  2007-10-21       Impact factor: 15.040

Review 9.  Heparin and heparan sulfate: structure and function.

Authors:  Dallas L Rabenstein
Journal:  Nat Prod Rep       Date:  2002-06       Impact factor: 13.423

10.  The structural plasticity of heparan sulfate NA-domains and hence their role in mediating multivalent interactions is confirmed by high-accuracy (15)N-NMR relaxation studies.

Authors:  Mehdi Mobli; Mathias Nilsson; Andrew Almond
Journal:  Glycoconj J       Date:  2007-12-13       Impact factor: 2.916

View more
  3 in total

1.  Structure Based Substrate Specificity Analysis of Heparan Sulfate 6-O-Sulfotransferases.

Authors:  Yongmei Xu; Andrea F Moon; Shuqin Xu; Juno M Krahn; Jian Liu; Lars C Pedersen
Journal:  ACS Chem Biol       Date:  2016-11-22       Impact factor: 5.100

2.  Changes in composition and sulfation patterns of glycoaminoglycans in renal cell carcinoma.

Authors:  Ebru Ucakturk; Orkun Akman; Xiaojun Sun; Dilek Ertoy Baydar; Anil Dolgun; Fuming Zhang; Robert J Linhardt
Journal:  Glycoconj J       Date:  2015-12-14       Impact factor: 2.916

3.  TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis.

Authors:  Anna Szeremeta; Agnieszka Jura-Półtorak; Aleksandra Zoń-Giebel; Krystyna Olczyk; Katarzyna Komosińska-Vassev
Journal:  J Clin Med       Date:  2022-07-20       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.